CTD HOLDINGS INC Form 10KSB April 02, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 10-KSB

(Mark One)

(X) ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  $\,$ 

For the fiscal year ended December 31, 2006

( ) TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-24930

CTD HOLDINGS, INC. (Name of small business issuer in its charter)

FLORIDA (State or other jurisdiction of incorporation or organization) 59-3029743 (I.R.S. Employer Identification No.)

27317 N. W. 78th Avenue, High Springs, FL 32643 (Address of principal executive offices) (Zip Code)

Issuer's telephone number: (386) 454-0887

Securities registered under Section 12(b) of the Exchange Act:

Title of each class Name of each exchange on which registered

None

Securities registered under Section 12(g) of the Exchange Act:

Class A Common Stock (Title of class)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (X) No( $_$ ).

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB (\_).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes (\_) No (X)

State issuer's revenues for its most recent fiscal year: \$512,313

1

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of a specified date within the past 60 days: \$130,443.93 based on the average high (\$.03) and low (\$.03) price as of March 8, 2007, of \$.03 per share.

Note: If determining whether a person is an affiliate will involve an unreasonable effort and expense, the issuer may calculate the aggregate market value of the common equity held by non-affiliates on the basis of reasonable asumptions, if the assumptions are stated.

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 15,918,489 shares of Common Stock as of March 22, 2007.

#### DOCUMENTS INCORPORATED BY REFERENCE

None

Transitional Small Business Disclosure Format (Check One): Yes (\_) No (X)

PART I

Item 1. Description of Business.

CTD Holdings, Inc. ("Us" or "the Company") was organized as a Florida corporation on August 9, 1990, with operations beginning in July 1992. We sell cyclodextrins ("Cyclodextrins" or "CDs") and related products to the food, pharmaceutical and other industries. We also provide consulting services in the area of commercialization of CD applications.

#### CDs

Cyclodextrins are molecules that bring together oil and water and have potential applications anywhere oil and water must be used together. Successful applications have been made in the areas of agriculture, analytical chemistry, biotechnology, cosmetics, diagnostics, electronics, foodstuffs, pharmaceuticals and toxic waste treatment. Stabilization of food flavors and fragrances is the largest current worldwide market for CD applications. The Company and others have developed CD-based applications in stabilization of flavors for food products; elimination of undesirable tastes and odors; preparation of antifungal complexes for foods and toiletries; stabilization of fragrances and dyes; reduction of foaming in foods; cosmetics and toiletries; and the improvement of quality, stability and storability of foods.

CDs can improve the solubility and stability of a wide range of drugs. Many promising drug compounds are unusable or have serious side effects because they are either too unstable or too insoluble in water. Strategies for administering currently approved compounds involve injection of formulations requiring pH adjustment and/or the use of organic solvents. The result is frequently painful, irritating, or damaging. These side effects can be ameliorated by CDs. CDs also have many potential uses in drug delivery for topical applications to the eyes and skin.

We believe the application of CDs in both OTC and ethical ophthalmic products provides the greatest opportunity for the successful and timely introduction of CD containing preparations for topical drug use.

We provide consulting services for the commercial development of new products containing CDs. Our revenues are derived from consulting, the

distribution of CDs, the manufacturing of selected CD complexes, and sales of our own manufactured and licensed products containing CDs.

#### CD Product Background

CDs are donut shaped circles of glucose (sugar) molecules. CDs are formed naturally by the action of bacterial enzymes on starch. They were first noticed and isolated in 1891 by a French scientist, Villiers, as he studied rotting potatoes. The bacterial enzyme naturally creates a mixture of at least three different CDs depending on how many glucose units are included in the molecular circle; six glucose units yield Alpha CD ("ACD"); seven units, beta CD ("BCD"); eight units, gamma CD ("GCD"). The more glucose units in the circle, the bigger the circle, or donut. The inside of this "donut" provides an excellent resting place for "oily" molecules while the outside of the donut is significantly compatible with water enabling clear stable solutions of CDs to exist in aqueous environments even when an "oily" molecule is carried within the donut hole. The net result is a molecular carrier that comes in small, medium, and large sizes with the ability to transport and deliver "oily" materials using water as the primary vehicle.

CDs are manufactured in large quantities by mixing appropriate enzymes with starch solutions, thereby reproducing the natural process. ACD, BCD and GCD can be manufactured by an entirely natural process and therefore are considered to be natural products. Additional processing is required to isolate and separate the CDs. The purified ACD, BCD, and GCD are referred to collectively as natural CDs (NCDs).

The chemical groups on each glucose unit in a CD molecule provide chemists with ways to modify the properties of the CDs, i.e. to make them more water soluble or less water soluble, thereby making them better carriers for a specific chemical. The CDs that result from chemical modifications are no longer considered "natural" and are referred to as chemically modified CDs ("CMCDs"). Since the property modifications achieved are often so advantageous to a specific application, the Company does not believe the loss of the "natural" product categorization will prevent its ultimate commercial use. It does, however, create a greater regulatory burden.

Our strategy is to sell CDs and to introduce products with little or no regulatory burden in order to minimize product expenses and create profitable revenue.

We currently sell our products for use in the pharmaceutical, food and industrial chemical industries.

#### CD Market

The food additive industry has been experimenting with CDs for many years. Now that commercial supply of these materials can be assured and regulatory approval is in place, the Company believes the food additive industry will continue to increase its use of CDs.

CDs have been used in a variety of food products in Japan for over 25 years. In 1999 the economic impact of CD's on the Japanese economy was reported to be \$2.6 billion. Within the last five years, more European countries have approved the use of CDs in food products. In the United States, major starch companies are renewing their earlier interest in CDs as food additives. Oral arguments for regulatory approval by the United States Food and Drug Administration ("FDA") have been accepted. As of November 3, 1997, BCD use as a

food additive in 10 categories of food products was confirmed to be generally recognized as safe (GRAS).

Applications of CDs in personal products and for industrial uses have appeared in many patents and patent applications. Procter & Gamble uses CDs in Bounce(R), a popular fabric softener and Febreze(R). Avon uses CDs in its dermal preparations using its Age Protective System APS(R). These uses will grow as the price of the manufactured CDs decrease or are perceived as acceptable in view of the value added to the products. In 2001 Janssen Pharmaceutica, a subsidiary of Johnson & Johnson received approval to market Sporanox(r), an oral and injectable formulation containing hydroxypropyl BCD.

In Japan at least twelve pharmaceutical preparations are now marketed which contain CDs. The CDs permit the use of all routes of administration. Ease of delivery and improved bioavailability of such well-known drugs as nitroglycerin, dexamethasone, PGE(1&2), and cephalosporin permit these "old" drugs to command new market share and sometimes new patent lives. Because of the value added, the dollar value of the worldwide market for products containing CDs and for complexes of CDs can be 100 times that of the CD itself.

#### CD Products

Our CD products include Trappsol(R), Aquaplex(R), and AP(TM)-Flavor product lines. The Trappsol product line consists of approximately 200 different varieties of CDs and the Aquaplex product line includes more than 60 different complexes of active ingredients with various CDs. In addition to these product lines, the Company introduced Garlessence(R) in the fourth quarter of 1995. Garlessence is the first ingestible product containing CDs to be marketed in the U.S. The Company also provides consulting services, research coordination, and the use of CD Infobase(TM), a comprehensive database of CD related information. The Company has protected its service and trade marks by registering them with the U.S. Patent and Trademark office. The following trademarks have been approved and are in use: Trappsol(R), and Aquaplex (R). These properties add to the intangible asset value of the Company. Since 2000, our Web Site at http://www.cyclodex.com, a major tangible asset has grown to be a leading Cyclodextrin information site on the Internet.

CTD purchases CD's from commercial manufacturers around the world including: Wacker Chemie - Munich, Germany; Nihon Shokuhin Kako - Tokyo, Japan; Roquette Freres - Le Strem, France; Cerestar Inc. - Hammond IN, USA. At the end of 2002, CTD became the exclusive distributor in North America of the CD products manufactured by Cyclolab R&D Labs in Budapest, Hungary. The Company does not manufacture cyclodextrins.

We have introduced many new products into our basic line of CDs and CD complexes--liquid preparations of CDs; relatively unprocessed, less expensive mixtures of the natural CDs; naturally modified CDs (glucosyl and maltosyl); and finally, excess production of custom complexes when those items are not proprietary or restricted by the customer.

#### Business Strategy

Our strategy has been and will continue to be to generate profitable revenue through sales of CD related products.

From inception through the current year, sales of CDs and CD derivatives have been sufficient to provide the necessary operational profitability to sustain the Company. Since these materials were simply purchased and resold, they had the least value-added attributes.

Presently, sales of CD complexes represent a majority of the Company's product sales revenues. Transition to the more value-added complexes continues and is desirable for increased profitability since higher margins can be maintained for these products. We have increased our list of major customers from 3 to 4 thereby continuing to reduce our dependency on sales to a very small core of repeat purchases.

We intend to increase our business development efforts in the food additive and personal products industries while continuing to build on our successes in the pharmaceutical industry.

Business development on behalf of the Company's clients will include the following: (i) negotiation of rights and/or licenses to CD-related inventions; (ii) consultation with manufacturers to establish customized manufacturing specifications; (iii) patentability assessments and strategic planning of patent activities; (iv) trade secret strategies; (v) regulatory interface; and (vi) strategic marketing planning.

The Company believes its competitive advantage lies in its experience and know how in the use and application of CDs, areas in which it believes it has few equals.

In addition to its licensing efforts, the Company intends to coordinate research studies in which it will retain a portion of the rights created as a result of the research work supported.

Assuming the availability of funds, the Company will negotiate licensing rights to its own selected inventions. Because of its comprehensive technical and patent database for CD-related inventions, the Company believes it is uniquely positioned to take advantage of constantly evolving licensing situations.

#### Marketing Plan

We believe the failure of businesses to exchange information about CD molecules has hindered a more rapid commercialization of CDs as safe excipients. We believe our philosophy of partnering and sharing will act as a catalyst to create momentum overcoming the inertia created by the previous conservatism and secrecy.

Our sales have always been direct, volatile and driven by the acceptance of CD's as beneficial excipients. Arrangements with large laboratory supply companies and several diagnostic companies have provided a strong sales base, that continues to diversify.

The Company has taken advantage of the propensity of researchers to use the Internet to gather information about new products by establishing a website with the unique and descriptive domain name "cyclodex.com".

We intend to work with clients in countries where current regulatory views include CDs as natural products acting as excipients to introduce beneficial pharmaceuticals improved by CDs.

Along with the new products themselves, the Company has created a licensable mark that may be used by other manufacturers wishing to take advantage of the improved aqueous delivery afforded by Trappsol CDs.

We intend to generate additional revenue through obtaining rights to

certain patents that we will sublicense to appropriate organizations or that we will use to develop our own proprietary products. Revenue would then be expected to result from sub-licensing royalties, sales of CD complexes to be used in the newly developed pharmaceuticals, and finally from the sales of the products to end-users.

Assuming an ongoing successful process of development, approval and adoption of CDs and CMCDs for pharmaceutical applications, the Company's objective is to initiate dialogue and be well prepared for partnerships with major food companies. Price is a primary concern in this market, but unlike pharmaceuticals where FDA permission for clinical testing may be obtained before actual FDA product approval, food companies cannot feed experimental formulations to test panels of consumers until the ingredients, i.e., the CDs, receive approval for human consumption. Therefore, the Company will work with the food companies and key university food research groups to initially evaluate non-taste applications. These questions will initially be explored using NCDs since commercial adoption will depend heavily upon the price of the CD selected and NCDs will always be the least expensive. The benefits derived from the use of CDs with expensive ingredients (e.g., flavors, fragrances) have already become accepted commercial uses for CMCDs (chemically modified CDs) and (naturally modified CD's) NMCDs.

#### Competition

The Company is currently a leading consultant in determining manufacturing standards and costs for CDs and CMCDs. However, there will always exist the potential for competition in this area since no patent protection can be comprehensive and forever exclusive. Nevertheless, there is a perceived barrier to entry into the CD industry because of the lack of general experience with CD complexation procedures. The Company has established a strong business relationship with one of the experts in this field -- Cyclolab in Hungary -- and has utilized the services and expertise of this laboratory. The Company believes this relationship provides a significant marketing lead time, and combined with a strong marketing presence, will give the Company a two to three year lead time advantage over its competitors.

In 2002 we became the exclusive North American distributor of the CD products manufactured by Cyclolab. We intend to form additional business relationships with Cyclolab in Hungary by creating a Cyclolab-USA laboratory facility and thereby strengthen our competitive advantage. The Company believes that it will be able to acquire, and is currently negotiating to acquire, all of the outstanding equity interest in Cyclolab for a total purchase price of \$1,525,000. The Company anticipates that in connection with its acquisition of Cyclolab, it would issue options to Cyclolab's current owners to purchase shares of CTD Holdings for a purchase price of \$0.01 per share.

#### Government Regulation

Under the Federal Food, Drug and Cosmetic Act ("Food and Drug Act"), the Food and Drug Administration ("FDA") is given comprehensive authority to regulate the development, production, distribution, labeling and promotion of food and drugs. The FDA's authority includes the regulation of the labeling and purity of the Company's food and drug products. In the event the FDA believes any company is not in compliance with the law, the FDA can institute proceedings to detain or seize products, enjoin future violations or assess civil and/or criminal penalties against that Company.

The FDA and comparable agencies in foreign countries impose substantial requirements upon the introduction of therapeutic drug products through lengthy and detailed laboratory and clinical testing procedures, sampling activities and

other costly and time consuming procedures. The extent of potentially adverse government regulations which might arise from future legislation or administrative action cannot be predicted.

Under present FDA regulations, FDA defines drugs as "articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man." The Company's product development strategy is to first introduce a product that will not be regulated by the FDA as a drug because all of its ingredients are natural products or is generally regarded as safe (GRAS) by the FDA. The Company is continually updated by counsel as to changes in FDA regulations that might affect the use of and claims for these products. There is no assurance that the FDA will not take the position that the Company's food and nutritional supplement products are subject to requirements relating to drug development and sale. The effect of such determination could be to limit or prohibit distribution of such products.

#### Employees

The Company employed three persons on a full time basis. None of the Company's employees belong to a union. The Company believes relations with its employees are good.

#### Item 2. Description of Property.

In 2000, the Company bought approximately 40 acres in western Alachua County, Florida, (the "Property") for a purchase price of \$210,000 which was paid for in part by a new first mortgage of \$150,000. The Property had been developed in part as a mushroom growing facility. While the Company has discontinued mushroom growing operations on the Property, the Company continues to use the Property as its corporate headquarters. Its present 6,000 sq.ft. facility is expected to be adequate to house the Company's operations for the foreseeable future.

The Company holds title to the Property in fee simple, subject to a purchase money mortgage securing repayment of a promissory note with a principal balance due of \$143,764 as of December 31, 2006. The principal amount due on the note accrues interest at a rate of seven and one-quarter (7.25) percent per year and neither the note nor the mortgage have a prepayment penalty. The maturity date of the note is December 5, 2005. The Property is not subject to any lease, option, purchase, or sales contracts, nor are there any immediate plans to renovate, improve, or further develop the Property. The Property is in a region that is experiencing moderate population and development growth which has increased the market value of the Property. Management believes the limits of insurance coverage are adequate for the Property.

The Property has a 6,000 sq.ft. facility from which the Company operates its corporate offices. The anticipated remaining useful life of the facility is undetermined, but in Management's estimate exceeds 25 years. The Property's federal tax basis, rate, and method are, respectively, \$162,000, 40 years, and straight-line. The realty tax rate and annual realty taxes assessed on the Property for the year ended December 31, 2006, are 23.2303 mils and \$3,124.00, respectively.

# Item 3. Legal Proceedings.

On February 7, 2007, Registrant and C.E. Rick Strattan filed suit in Circuit Court in Palm Beach County, Florida, (Case Number 2007CA001818XXXXMB) seeking the return of the Class A Preferred Share and damages from defendants Eline Entertainment Group, Inc., Eline Holding Group, Inc., Yucatan Holding

Company, Steven T. Dorrough, Jayme Dorrough, and Barry Rothman, based on representations made in connection with the Share Exchange Agreement dated August 11, 2005, as amended and the enforcement of the agreement.

Item 4. Submission of Matters to a Vote of Security Holders. None

#### Part II

Item 5. Market for Common Equity and Related Stockholder Matters.

In October 1994, the Company's securities began trading on the OTC Bulletin Board and in the over-the-counter market "pink sheets" under the symbol CTDI. In 2000, CTDI did a 2 for 1 split of its common shares from approximately 2.3 million to 4.6 million issued and outstanding. In conjunction with that restructuring, we changed the name of CTDI to CTD Holdings, Inc; CTDI was then incorporated as a Florida corporation and became a wholly owned subsidiary of CTD Holdings, Inc. In 2000 CTD Holdings, Inc. changed its trading symbol to CTDH.OB and currently trades on the OTC Bulletin Board as CTDH.OB. Since the commencement of trading of the Company's securities, there has been an extremely limited market for its securities. The following table sets forth high and low bid quotations for the quarters indicated as reported by the OTC Bulletin Board.

....

2005 First Quarter \$ 0.075 \$ 0.07	1
Second Quarter \$ 0.074 \$ 0.0"	13
Third Quarter \$ 0.076 \$ 0.07	2
Fourth Quarter \$ 0.049 \$ 0.04	17
2006 First Quarter \$ 0.09 \$ 0.03	
Second Quarter \$ 0.07 \$ 0.04	
Third Quarter \$ 0.05 \$ 0.03	3
Fourth Quarter \$ 0.05 \$ 0.02	2

Over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions and may not represent actual transactions.

#### Holders

As of March 22, 2007, the number of holders of record of shares of common stock, excluding the number of beneficial owners whose securities are held in street name was approximately 77.

#### Dividend Policy

The Company will not pay any cash dividends on its common stock in 2006 because it intends to retain its earnings to finance the expansion of its business. Thereafter, declaration of dividends will be determined by the Board of Directors in light of conditions then existing, including without limitation the Company's financial condition, capital requirements and business condition.

Recent Sales of Unregistered Securities

None.

Item 6. Management's Discussion and Analysis or Plan of Operation.

#### Introduction

CTD Holdings, Inc. (referred to as the "Company," "CTD," or "we," "us," and "our") began operations in 1990. Our revenues are principally derived from the resale of cyclodextrins and cyclodextrin complexes. Our sales are primarily to major chemical supply houses around the world, pharmaceutical companies, food companies for research and development and to diagnostics companies. We acquire our products principally from outside the United States, largely from Japan and Hungary, but are gradually finding satisfactory supply sources in the United States. While we enjoy better supply prices from outside the United States, rising shipping costs are making domestic sources more competitively priced. To add value to our products, we maintain a database of patented and patent pending uses of cyclodextrins as recorded by the United States Patent & Trademark Office. We also maintain a database that includes patents issued in many other countries of the World. This information is available to our customers. We also offer our customers our knowledge of the properties and potential new uses of cyclodextrins and complexes.

As most of our customers use our cyclodextrin products in their research and development activities, the timing, product mix, and volume of their orders from us are unpredictable. We also have four major customers who have a significant effect on our revenues when they increase or decrease their research and development activities that use cyclodextrins. We keep in constant contact with these customers as to their cyclodextrin needs so we can maintain the proper inventory composition and quantity in anticipation of their needs. The sales to major customers and the product mix and volume of products sold has a significant effect on our revenues and gross profit. These factors contribute to our potentially significant revenue volatility from quarter to quarter and year to year.

In 2004, we amended the Company's Articles of Incorporation authorizing a series of "blank check" preferred stock consisting of 5,000,000 shares and creating a series of Series A Preferred Stock, setting forth its designations, rights and preferences. The more significant right is Series A Preferred shareholders vote with the holders of common stock on all matters submitted to a vote of our shareholders. Share of Series A Preferred Stock are entitled to one vote more than one-half of all votes entitled to be cast by all holders of voting capital stock of the Company on any matter submitted to holders of common shares so as to ensure that the votes entitled to be cast by the holder of the Series A Preferred Stock are equal to at least a majority of the total of all votes entitled to be cast by the holder of all votes entitled to C.E. Strattan, our majority shareholder in exchange for 1,029,412 shares of common stock held by him, which he voluntarily surrendered to the Company and were cancelled. Effective August 11, 2005, C.E.

Strattan contractually transferred the one outstanding share of Series A Preferred Stock to Eline Entertainment Group, Inc. (Eline). The agreement with Eline provides for advances to the Company of up to an aggregate of \$1,500,000 to acquire Cyclolab, at Eline's sole discretion. Eline is an SEC reporting company currently not in reporting compliance. In September 2006, the company's President, Mr. Strattan, demanded, in accordance with the expired contract, the return of the Series A Preferred Stock in the form of a stock power authorization since the physical share never left the possession of its original owner, Mr. Strattan. The demand letter was sent to the address given in the contract and was never acknowledged nor responded to by Eline. The Company has filed a legal action with regard to its agreement with Eline. See "Legal Proceedings".

Liquidity and Capital Resources

Our cash and short-term investments remained at approximately \$159,000 as of December 31, 2006. Our cash flow from operations for 2006 was \$26,000 compared to \$129,000 for 2005. The decreased cash flow from operations from 2005 is due primarily to \$112,000 of expenses related to the attempted acquisition of Cyclolab. While we reported a net loss in 2006 of \$102,000, we had \$134,000 in noncash expenses in 2006. The decreased loss is due a number of factors. We realized a increase of \$88,000 in revenue and a \$150,000 decrease in selling, general and administrative expenses (excluding \$112,000 of costs related to the attempted acquisition of Cyclolab) in 2006 compared to 2005. The largest decrease in expenses was in stock compensation and bonuses (\$38,000 decrease). In 2006, we recorded a \$50,000 impairment expense on the Collection; in 2005, we reported a net \$161,000 gain on the Collection (net of a \$42,000 impairment expense), and a \$225,000 deferred tax valuation allowance expense.

We believe our working capital is sufficient to run our operations at current and expected future operating levels into the near future. We do not require capital in the next twelve months for normal operations. During 2005, we signed a letter of intent to acquire a majority interest in Cyclolab, located in Hungary. During 2006, we were unable to obtain the capital necessary to acquire Cyclolab and discontinued our efforts to do so. We expensed \$112,000 in legal, accounting, and travel costs associated with the Cyclolab acquisition in 2006.

Controlling cash expenses continues to be management's primary fiscal tool. However, growth requires increased expenditures and while we feel it is appropriate during the current growth stage to engage consultants that can help the Company in financial areas outside its expertise, these consulting fees will act to reduce profitability. We are working hard to increase revenues to balance these new expenses, but cannot be sure such effort will be enough in the short term to sustain financial performance like that of the recent past.

During 2004, we acquired a sports memorabilia collection from our President. We received \$5,000 in 2005 and there have been no sales in 2006. We sold no Collection items in 2006. Beginning in 2007 we plan to begin using E-Bay to list items for sale. We have no prior experience in retail sales or in selling items on E-Bay. During 2006 and 2005, we recorded a valuation allowance of \$50,000 and \$42,000, respectively on the collection due to the lack of marketability.

Beginning in 2003, we began improvements and renovations of our corporate office and have invested \$123,000 through December 31, 2004. During 2005, we suspended our improvement and renovations program to redirect our financial resources to the Cyclolab acquisition. During 2006, we capitalized \$17,000. We remain committed to a Research Park facility for the 40-acre site. The office renovations will be followed by improved security operations and modest guest facilities. Contingent on the Company's ability to financially support modest expansions that will lead to a formal site plan, we anticipate spending at least another \$100,000 over the next two years to position the Company to initiate a 5-year plan for a new Cyclodextrin Research Park.

In April 2004, we acquired a collection of sports memorabilia from our majority shareholder and President in exchange for 1,029,412 shares of common stock. While we received a \$400,000 appraisal on the collection, we recorded this asset for \$106,000, which represents our majority shareholder's cost basis. We also engaged a consultant under a one year contract to liquidate the collection for not less than 75% of its book value as stated in any of the leading collectibles industry guide books. This agreement expired in April 2005. The consultant was issued 250,627 shares of common stock valued at \$100,250, which we expensed in 2004. We also agreed to an option whereby the consultant could have acquire the

entire collection for \$200,000. We recorded the fair value of this option (\$204,000) as a liability and a charge to operations in 2004. In 2005, we recorded a \$204,000 gain when the option expired.

We issued 1,791,873 shares and 1,443,151 shares of our common stock to employees for compensation earned under employment agreements for 2006 and 2005, respectively.

We have no off-balance sheet arrangements as of December 31, 2006.

#### Results of Operations and Critical Accounting Policies and Estimates

The results of operations are based on the preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States. The preparation of consolidated financial statements requires management to select accounting policies for critical accounting areas as well as estimates and assumptions that affect the amounts reported in the consolidated financial statements. The Company's accounting policies are more fully described in Note 1 of Notes to Consolidated Financial Statements. Significant changes in assumptions and/or conditions in our critical accounting policies could materially impact the operating results. We have identified the following accounting policies and related judgments as critical to understanding the results of our operations.

Baseball Memorabilia Collection Asset

The recoverability of our baseball memorabilia collection asset is evaluated annually or more frequently if impairment indicators exist. Indicators of impairment include losses realized on sales and our future operating plans. If impairment indicators exist, we evaluate the recoverability of the asset using an overall collection basis based on undiscounted expected future cash flows based on individual collection piece values published in auction-house guidebooks and/or reputable trade publications and price guides, less estimated costs to sell the collection. The recorded value for the collection is not expected to be recovered through undiscounted future cash flows is written down to current fair value, which is generally determined from estimated discounted future net cash flows. We recorded an impairment allowance for \$50,000 and \$42,000 as of December 31, 2006 and 2005, respectively. At December 31, 2006, our valuation allowance equaled our recorded cost of the Collection.

#### Long-Lived Assets

The recoverability of long-lived assets is evaluated annually or more frequently if impairment indicators exist. Indicators of impairment include historical financial performance, operating trends and our future operating plans. If impairment indicators exist, we evaluate the recoverability of long-lived assets on an operating unit basis based on undiscounted expected future cash flows before interest for the expected remaining useful life of the operating unit. Recorded values for long-lived assets that are not expected to be recovered through undiscounted future cash flows are written down to current fair value, which is generally determined from estimated discounted future net cash flows for assets held for use or net realizable value for assets held for sale.

At December 31, 2006, we have idle buildings located on the same property as our corporate offices that were used in our former mushroom farming operation. The carrying value of these idle long-lived assets is \$77,000. We have determined the fair value of these assets exceeds this carrying value based on recent real estate appraisal. We continue to depreciate the assets over their estimated

useful life. Should the value of these assets decline, we may be required to record an impairment charge that could be significant. During 2006, the Company recorded an \$12,500 impairment allowance for an autoclave not currently used in the Company's operation.

Valuation Allowance on Deferred Tax Assets

SFAS 109, "Accounting for Income Taxes" requires that deferred tax assets be evaluated for future realization and reduced by a valuation allowance to the extent we believe a portion will not be realized. We consider many factors when assessing the likelihood of future realization of our deferred tax assets including our recent cumulative earnings experience, expectations of future taxable income, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. At December 31, 2006, our net deferred tax assets are \$515,000, comprised principally of net operating loss carryforwards (NOLs), with the remaining portion related to temporary timing differences between tax and financial reporting. Classification of deferred tax assets between current and long-term categories is based on the expected timing of realization, and the valuation allowance is allocated on a prorata basis.

We reported a financial net loss of \$(101,000), During 2006, we maintained our deferred tax asset valuation allowance at 100% based on the Company's current loss, its history of prior losses, and our sales volatility that collectively reduces the chance of realization of our deferred tax assets. In 2005, we increased our valuation allowance to 100% from 48%, which resulted in income tax expense of \$225,000. The range of possible judgments relating to the valuation of our deferred tax asset is very wide. For example, in 2005 we determined the weight of available evidence did not support a decision that a portion of our deferred tax assets will be realized, resulting in the income tax expense of \$225,000. Alternatively, if we had concluded that the weight of available evidence supported a decision that substantially all of our deferred tax assets may be realized, we would have a substantial income tax benefit in our statement of operations.

Significant judgment is required in making this assessment, and it is very difficult to predict when, if ever, our assessment may conclude our deferred tax assets is realizable.

#### 2006 Compared to 2005

Total product sales for 2006 were \$542,000, a 19% increase over 2005 sales of \$454,000. Our major customers continue to be repeat purchasers. In 2006, our four largest customers accounted for 58% of our sales; the largest accounted for 22% of sales. In 2005, our four largest customers accounted for 68% of our sales; the largest accounted for 27% of sales.

Our gross profit margin of 77% for 2006 decreased significantly compared to 85% for 2005. Changes in the product mix in sales has a significant effect on our overall gross profit percentage. For 2006, we acquired more inventory from Cyclolab due to our acquisition plan, which often was more expensive than other suppliers. Management expects our gross profit to remain in the 70% range for 2007.

Our SG&A expenses decreased to \$351,000 in 2006 from \$500,000 in 2005 (excluding \$112,000 of costs in 2006 related to the attempted acquisition of Cyclolab), primarily as a result of a reduction in stock based compensation to officers and consultants. In 2006, we incurred \$112,000 in direct expenses related to consulting, legal and accounting fees incurred as a result of the Company's attempted acquisition of Cyclolab.

For 2006 and 2005, the Company has employment agreements with two officers for total monthly salaries of \$4,900. In addition, each month the officers are awarded shares of common stock restricted by Rule 144. The number of shares awarded is equal to \$6,000 divided by eighty percent of the closing price of the Company's common stock on the last day of each month. The Company recognizes an expense equal to the fair value of the stock determined using the average stock closing trading price for the month multiplied by number of shares awarded for that month. The stock is subject to trading restrictions under Rule 144. For 2006, the Company awarded 1,791,873 shares and recognized an expense of \$84,000 for stock awarded under these agreements. For 2005, the Company awarded 1,443,151 shares and recognized an expense of \$92,000 for stock awarded under these agreements for 2007.

In August 2005, the Company issued 1,000,000 shares of common stock registered under Form S-8 to financial consultants and charged an expense of \$60,000 in 2005, which equaled the fair value of the stock on the date of the award. The Company also issued 500,000 shares of common stock registered under Form S-8 to its President and majority shareholder and charged an expense of \$30,000 in 2005, which equaled the fair value of the stock on the date of the award.

In April 2004, we acquired a collection of sports memorabilia from our majority shareholder and President. We engaged a consultant to liquidate the collection. The consultant was issued 250,627 shares of common stock valued at \$100,250, which was expensed. This contract expired in March 2005, and the unsold portion of the Collection was returned to the Company. The Company continues to explore its options regarding liquidation of the Collection. In 2004, we issued the consultant an option to acquire the entire collection for \$200,000. We recorded the fair value of this option (\$204,000) as a charge to operations during 2004. In 2005, this option expired and we recorded a gain of \$204,000. We received net proceeds of \$5,000 from the sales of items from the collection in 2005.

We expect an increase in our 2007 legal expenses as the result of our legal actions related to Eline Entertainment, Inc.

For 2006, we maintained the valuation allowance of our deferred tax asset at 100%. In 2005, we increased the valuation allowance on our deferred tax asset to 100% from 48%, resulting in an income tax expense of \$225,000 for 2005. This increase was based primarily on net operating losses realized in 2005 and 2004. Our deferred tax asset is based on our net operating loss carryforward.

We recognized a net loss for 2006 of (101,000) compared to a net loss of (172,000) for 2005.

We will continue to introduce new products that will increase sales revenue and implement a strategy of creating or acquiring operational affiliates and/or subsidiaries that will use CD's in herbal medicines, waste-water remediation, pharmaceuticals, and foods. We also intend to pursue exclusive relationships with major CD manufacturer(s) and specialty CD labs to distribute their products. We continue to be the exclusive distributor in North America of the CD products manufactured by Cyclolab Research Laboratories in Budapest, Hungary.

In keeping with its commitment to use the internet as a major advertising and public relations outlet, we continue to maintain our web site. This asset has been instrumental in creating and maintaining a worldwide leadership role for us in the implementation of research and commercialization of CD applications. We believe the maintenance and growth of our web site will return that investment many times.

Forward-looking Statement

All statements other than statements of historical fact in this report are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, and are based on management's current expectations of the Company's near term results, based on current information available and pertaining to the Company. The Company assumes no obligation to update publicly any forward-looking statements. Actual results may differ materially from those projected in the forward-looking statements. These forward-looking statements involve risks and uncertainties, including, but not limited to, the following: demand for Cyclodextrins; changes in governmental laws and regulations surrounding various matters, such as labeling disclosures; production and pricing levels of important raw materials; difficulties of delays in the development, production, testing and marketing of products; and product margins and customer product acceptance.

Item 7. Financial Statements.

#### BAUMANN, RAYMONDO & COMPANY, P.A. 405 NORTH REO STREET, SUITE 200 TAMPA, FL 33609

Report of Independent Registered Public Accounting Firm

To the Board of Directors CTD Holdings, Inc. High Springs, Florida

We have audited the consolidated balance sheet of CTD Holdings, Inc. and subsidiary as of December 31, 2006, and the related consolidated statements of operations, stockholders' equity and cash flows for the years ended December 31, 2006 and 2005. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provided a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of CTD Holdings, Inc. and subsidiary as of December 31, 2006, and the results of their operations and their cash flows for the years ended December 31, 2006 and 2005, in conformity with U.S. generally accepted accounting principles.

\s\ Baumann, Raymondo & Company, P.A.

Baumann, Raymondo & Company PA Tampa, Florida February 12, 2007

CTD HOLDINGS, INC. CONSOLIDATED BALANCE SHEET DECEMBER 31, 2006

ASSETS

CURRENT ASSETS Cash and cash equivalents Accounts receivable Inventory Investment due from related party Other current assets	Ş	23,629 59,109 79,747 135,540 24,113
Total current assets		322,138
PROPERTY AND EQUIPMENT, NET		334,182
OTHER		
Loan to officer Intangibles, net of accumulated		16,514
amortization of \$3,800 Idle property and equipment		10,267 77,361
Total other assets		104,142
TOTAL ASSETS	\$ ====	760,462

The accompanying notes to consolidated financial statements are an integral part of this statement.

F-2

### CTD HOLDINGS, INC. CONSOLIDATED BALANCE SHEET DECEMBER 31, 2006 (Continued)

# LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES	
Accounts payable and accrued expenses	\$ 52 <b>,</b> 166
Current portion of long-term debt	6,182
Total current liabilities	 58,348
LONG-TERM LIABILTIES	
Long-term debt, less current portion	142,002

STOCKHOLDERS' EQUITY Common stock, par value \$.0001 per share, 100,000,000 shares authorized, 15,705,541 shares issued and outstanding

1,571

Preferred stock, par value \$.0001 per share,		
5,000,000 shares authorized; Series A, 1 share		
issued and outstanding		-
Additional paid-in capital		2,881,262
Accumulated deficit	(	2,322,721)
Total stockholders' equity		560,112
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$	760,462
	===	

The accompanying notes to consolidated financial statements are an integral part of this statement.

F-3

## CTD HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005

		2006	2	005
PRODUCT SALES	\$	542,313	\$	454,360
COST OF PRODUCTS SOLD		125,188		66 <b>,</b> 657
GROSS PROFIT		417,125		387,703
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES Selling, general and administrative Acquisition costs - Cyclolab		350,675 112,353		500,316
Total, selling, general and administrativ Expenses	е 	463,028		500,316
SPORTS MEMORABILIA COLLECTION Gain on sales Other income (expense)		(50,402)		
OTHER INCOME (EXPENSE) Investment and other income Interest expense Loss on disposal of equipment		19,365 (11,049) (13,836)		14,736 (13,956)
Total other income (expense)		(5,520)		780
NET INCOME (LOSS) BEFORE INCOME TAXES		(101,825)		52 <b>,</b> 539
INCOME TAXES		_		(225,000)
NET INCOME (LOSS)		(101,825)	\$	

NET INCOME (LOSS) COMMON SHARE:	\$	(.007)	\$	(.014)
	=====			
Weighted average number of				
common shares outstanding	14,	815,279	12,0	17,790
	=====			

The accompanying notes to consolidated financial statements are an integral part of these statements.

F-4

## CTD HOLDINGS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005

	COMMON	STOCK	PREFEF	RRED STOCK	ADDITIONAL PAID-IN	ACCUMUL
	SHARES	PAR VALUE	SHARES	PAR VALUE		DEFIC
Balance, December 31, 2004	10,956,517	\$ 1,096	1	ş –	\$ 2,615,288	\$ (2,048,
Employment agreements	1,943,151	194	-	-	122,110	
Shares issued for services	1,000,000	100	-	-	59 <b>,</b> 900	
Net loss	_	-	_	_	_	(172,
Balance, December 31, 2005	13,899,668	1,390	1	-	2,797,298	(2,220,
Shares issued under employment agreements	1,791,873	179	-	-	83,406	
Shares issued for services	14,000	2	-	-	558	
Net loss	-	-	_	-	_	(101,
Balance, December 31, 2006	15,705,541	\$ 1,571	1	\$	\$ 2,881,262	\$ (2,322,

The accompanying notes to consolidated financial statements are an integral part of these statements.

F-5

CTD HOLDINGS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Increase (Decrease) in Cash and Cash Equivalents

DECEMBER 31, 2006 AND 2005

	2006	2005
CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss)	\$ (101 825)	\$ (172,461)
Net Income (1055)	Ş (101,023)	Ş (172,401)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:		
Depreciation and amortization	27,463	35,011
Gain on sale of sports memorabilia collection		(2,902)
Loss on disposal of equipment	13,836	-
Deferred income taxes		225,000
Impairment adjustment-sports memorabilia coll.	50,402	42,000
Stock issued for services	-	60,000
Expiration of call option-sports memorabilia coll.	-	(203,470)
Stock compensation to employees	84,145	122,304
Increase or decrease in:		
Accounts receivable	(22,707)	22,620
Inventory	(25,162)	(3,586)
Prepaid expenses	(24,113)	
Accounts payable and accrued expenses	24,075	4,251
Total adjustments	127,939	301,228
Net cash provided by (used in)operating		
activities	26,114	128,767
CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of sports memorabilia coll. Purchase of property and equipment Purchase of certificate of deposit Redemption of certificate of deposit Loan costs incurred	(27,628) - 131,381	4,545 (22,576) (91,048) - (3,872)
Investment with related party	(110,540)	
Net cash provided by (used in) investing activities	(6,787)	(137,951)
CASH FLOWS FROM FINANCING ACTIVITIES		
Doumonts on long-torm dobt	(6 742)	16 1111
Payments on long-term debt	(6,743)	
Payment on loan payable to stockholder Loan to shareholder	(16,514)	(50,131)
Received from shareholder	(10, 514)	2,084
Net cash used in financing activities	(26,724)	(54,161)
Net increase (decrease) in cash and cash equivalents	(7,397)	(63,345)
CASH AND CASH EQUIVALENTS, beginning of period	31,026	94,371
CASH AND CASH EQUIVALENTS, end of period	\$  23,629 ======	\$   31,026 ======

#### CTD HOLDINGS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Increase (Decrease) in Cash and Cash Equivalents DECEMBER 31, 2006 AND 2005 (Continued)

	2006		2005	
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION				
Cash paid for interest	\$	11,049	\$	13,686
	====		===	
Cash paid for income taxes	\$	-	\$	_
	====		===	
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITY				
Common stock issued for services	\$	84,145	\$	182,304
	====		===	

The accompanying notes to consolidated financial statements are an integral part of these statements.

#### CTD HOLDINGS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2006 AND 2005

#### (1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

The following is a summary of the more significant accounting policies of CTD Holdings, Inc. and Subsidiary (the Company) that affect the accompanying consolidated financial statements:

(a) ORGANIZATION AND OPERATIONS - The Company was incorporated in August 1990, as a Florida corporation with operations beginning in July 1992. The Company is engaged in the marketing and sale of cyclodextrins and related products to food, pharmaceutical and other industries. The Company also provides consulting services related to cyclodextrin technology.

(b) BASIS OF PRESENTATION - The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.

(c) CASH AND CASH EQUIVALENTS - For the purposes of reporting cash flows, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

(d) ACCOUNTS RECEIVABLE - Accounts receivable are stated at the amount management expects to collect from outstanding balances. Based on management's assessment of the credit history with customers having outstanding balances and current relationships with them, it has concluded that realization losses on balances outstanding at year-end will be immaterial.

(e) PROPERTY AND EQUIPMENT - Property and equipment are recorded at cost. Depreciation on property and equipment is computed using primarily the straight-line method over the estimated useful lives of the assets, which range

from three to forty years. In accordance with Statement of Financial Accounting Standards No. 121 "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of," the Company periodically reviews its long-lived assets to determine if the carrying value of assets may not be recoverable. If an impairment is identified, the Company recognizes a loss for the difference between the carrying amount and the estimated value of the asset.

(f) INVENTORY - Inventory consists of cyclodextrin products purchased for resale and chemical complexes. Inventory is recorded at the lower of cost (first-in, first-out) or market.

(g) INTANGIBLES - Intangible assets consist of loan costs and other intangibles recorded at cost. Intangible are amortized using the straight-line method over their respective estimated useful lives.

(h) SPORTS MEMORALBILIA COLLECTION - The sports memorabilia collection (Collection) was acquired from the Company's President and majority shareholder in 2004 in exchange for common stock of the Company (see Note 13). The Collection consists principally of baseball cards, but also includes a variety of other collectible sport memorabilia. The Collection was recorded at the cost basis of the President and majority shareholder, which was less than the estimated fair value. The Company records gains as the Collection is sold and cash is received, net of expenses. The cost of the Collection is expensed at 26.5% of gross proceeds from the sale of the Collection. The 26.5% cost allocation is based on the recorded cost of the Collection divided by the estimated fair value of the Collection. The Company periodically reviews the fair value of the Collection for impairment.

(i) REVENUE RECOGNITION - Revenues are recognized when products are shipped.

(j) ADVERTISING - Advertising costs are charged to operations when incurred.

(k) START-UP COSTS - Start-up costs are expensed as incurred.

(1) NET INCOME (LOSS) PER COMMON SHARE - Net income (loss) per common share is computed in accordance with the requirements of Statement of Financial Accounting Standards No. 128 (SFAS 128). SFAS 128 requires net income (loss) per share information to be computed using a simple weighted average of common shares outstanding during the periods presented. For stock awarded under employment agreements (see Note 2), the monthly stock awarded is treated as issued on the 15th day of each month earned for purposes of computing the weighted average outstanding shares.

(m) STOCK BASED COMPENSATION - The Company follows the requirements of Statement of Financial Accounting Standard No. 123(R) "Share-Based Payment." The Company has employment agreements which call for stock to be awarded to employees each month. The Company recognizes an expense equal to the fair value of the stock determined using the average stock closing trading price for the month multiplied by number of shares awarded for that month. The Company also issues periodic stock bonuses to employees. The Company records an expense equal to the fair value of the stock on the closing trading price of the stock on the day awarded.

(n) RECLASSIFICATIONS - Certain amounts in the 2005 financial statements have been reclassified for comparative purposes to conform with the 2006 presentation.

(o) NEW ACCOUNTING PRONOUNCEMENTS - The Financial Accounting Standards Board ("FASB") has issued several new standards, which have implementation dates subsequent to the Company's year end. Management does not believe that any of these new standards will have a material impact on the Company's financial position, results of operations or cash flows.

(p) USE OF ESTIMATES - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

#### (2) COMMITMENTS AND CONTINGENCIES

In August 2005, the Company issued 1,000,000 shares of common stock registered under Form S-8 to financial consultants and charged an expense in 2005 for 60,000, which equaled the fair value of the stock on the date of the award. The Company also issued 500,000 shares of common stock registered under Form S-8 to its President and majority shareholder and charged expense in 2005 for 30,000, which equaled the fair value of the stock on the date of the award.

For 2006, the Company has employment agreements with two officers for total monthly salaries of \$4,900. In addition, the officers are awarded shares of common stock each month. The number of shares due is equal to \$6,000 divided by eighty percent of the closing price of the Company's common stock on the last day of each month. The Company recognizes an expense equal to the fair value of the stock determined using the average stock closing trading price for the month multiplied by number of shares awarded for that month. The stock is subject to trading restrictions under Rule 144. For 2006, the Company awarded 1,791,873 shares and recognized an expense of \$83,585 for stock awarded under these agreements. For 2005, the Company awarded 1,943,152 shares and recognized an expense of \$122,304 for stock awarded under these agreements. Both agreements have been extended through December 31, 2007. The Company also awarded 14,000 shares of stock to its employees and recorded and expense of \$560.

On February 7, 2007, Registrant and C.E. Rick Strattan filed suit in Circuit Court in Palm Beach County, Florida, (Case Number 2007CA001818XXXXMB) seeking the return of the Class A Preferred Share and damages from defendants Eline Entertainment Group, Inc., Eline Holding Group, Inc., Yucatan Holding Company, Steven T. Dorrough, Jayme Dorrough, and Barry Rothman, based on representations made in connection with the Share Exchange Agreement dated August 11, 2005, as amended and the enforcement of the agreement.

#### (3) PROPERTY AND EQUIPMENT

Property and equipment as of December 31, 2006, consists of:

Land Buildings and improvements Machinery and equipment Office furniture and equipment	Ş	80,000 241,312 20,230 58,961
		400,503
Less: accumulated depreciation		83,769
		316,734
Construction in progress		17,448

Property and equipment, net \$ 334,182

\_\_\_\_\_

\_\_\_\_\_

The carrying value of remaining idle long-lived assets related to a former mushroom farming operation was \$77,361 at December 31, 2006.

(4) CONCENTRATIONS OF CREDIT RISK:

Significant concentrations of credit risk for all financial instruments owned by the Company, are as follows:

(a) DEMAND AND CERTIFICATE OF DEPOSITS - The Company has demand and certificate of deposits in financial institutions that are insured by the Federal Deposit Insurance Corporation up to \$100,000. At December 31, 2006, the demand and certificate deposit bank balance was \$24,000. The Company has no policy of requiring collateral or other security to support its deposits.

(b) ACCOUNTS RECEIVABLE - The Company's accounts receivable consist of amounts due primarily from food and pharmaceutical companies located primarily in the United States and the United Kingdom. Two customers accounted for 77% of the accounts receivable balance at December 31, 2006. The Company has no policy requiring collateral or other security to support its accounts receivable.

(c) INVESTMENT WITH RELATED PARTY - The Company has an oral agreement for investment services with a nonprofit organization. The Company's president is also the president of the nonprofit organization. The funds are invested by the nonprofit in a money market account. The Company earns a proportional share of the interest earned in the account. The Company has no policy of requiring collateral or other security to support this amount.

F-8

#### CTD HOLDINGS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2006 AND 2005

(5) MAJOR CUSTOMERS AND SUPPLIERS:

In 2006, three major customers accounted for approximately 49% of total sales. In 2005, three major customers accounted for approximately 58% of total sales.

Substantially all 2006 inventory purchases were from three vendors. Substantially all 2005 inventory purchases were from two vendors.

The Company has only one source for certain manufacturing inventory. However, the Company has manufactured these products in the past and could do so again, if necessary. There are multiple sources for its other inventory products.

(6) LONG-TERM DEBT:

Long-term debt consists of the following as of December 31, 2006:

Mortgage note payable to bank, payments of \$1,163 due monthly including principal and interest at 7.25%, collateralized by land and buildings with a cost of \$210,000 \$ 143,764

Note payable to financing company, payments of		
\$288 due monthly, including principal and interest,		
at 6%, collateralized by vehicle with a cost		
of \$14,881		4,420
Total long-term debt		148,184
Less current portion		(6,182)
Long-term debt, less current portion	\$	142,002
	==-	

Maturities on long-term debt as of December 31, 2006 over the next five years and thereafter are as follows:

Year ending December 31,	Amount
2007 2008 2009 2010 2011 2012 and thereafter	\$ 6,182 5,362 4,238 4,556 4,897 122,949
	\$ 148,184 =========

#### (7) RELATED PARTY TRANSACTIONS:

The President (who is also the majority common stockholder) had previously provided loans to the Company. The Company paid the loan off in full during the year ended December 31, 2006. The loan was unsecured and interest accrued at 4.17%. Interest expense related to the loan totaled \$43 and \$1,301 for the years ended December 31, 2006 and 2005, respectively.

During 2006, the President (who is also the majority common stockholder) borrowed \$16,514. The loan is unsecured and interest accrues at 5%. This loan was a prohibited transaction under Section 402 of the Sarbanes-Oxley Act and was repaid on February 2, 2007.

#### (8) FAIR VALUE OF FINANCIAL INSTRUMENTS:

Statement of Financial Accounting Standards No. 107 "Disclosures about Fair Value of Financial Instruments" requires disclosure of fair value to the extent practicable for financial instruments, which are recognized or unrecognized in the consolidated balance sheet. The fair value of all financial instruments approximates carrying value due to the short-term maturity of the instruments. The fair value of the financial instruments is not necessarily representative of the amount that could be realized or settled, nor does the fair value amount consider the tax consequences of realization or settlement.

The Company follows the provisions of Statement of Financial Accounting Standard No. 109 "Accounting for Income Taxes." Differences between accounting rules and tax laws cause differences between the basis of certain assets and liabilities for financial reporting purposes and tax purposes. The tax effect of these differences, to the extent they are temporary, is recorded as deferred tax assets and liabilities. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred assets and liabilities. Temporary differences which give rise to deferred tax assets and liabilities consist of net operating loss carryforwards, accelerated depreciation methods for income tax purposes and interest accrued to related parties but not for tax purposes until paid.

The Company has available at December 31, 2006, unused operating loss carryforwards totaling approximately \$ 1,647,000 that may be applied against future taxable income. If not used, the carryforwards will expire as follows:

Year Ending December 31,	Amount
2009	\$ 760,000
2010	195,000
2017	206,000
2020	280,000
2021	71,000
2024	66,000
2025	37,000
2026	32,000
Total	\$ 1,647,000
	=========

If all of the operating loss carryforwards and temporary deductible differences were used, the Company would realize a deferred tax asset of approximately \$515,000 based upon expected income tax rates. Under Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes", the deferred tax asset should be reduced by a valuation allowance if it is likely that all or a portion of it will not be realized. Realization depends on generating sufficient taxable income before the expiration of the loss carryforwards.

At December 31, 2002, management determined that a 100% valuation allowance was appropriate. For 2003 and 2002, the Company realized net income and utilized approximately \$240,000 of its net operating loss carryforward to offset its current income tax liabilities. In 2003, Management determined that a reduction in the valuation allowance to 43% from 100% of the future tax benefit was appropriate, which resulted in the recognition of a \$225,000 deferred tax asset and a income tax benefit. In 2004, Management increased it valuation allowance percentage to 48% resulting in no income tax expense or benefit for change in its deferred tax asset. At December 31, 2005, Management increased the valuation allowance to 100% due primarily to net losses realized for 2004 and 2005. This resulted in income tax expense of \$225,000 for 2005. For 2006, management continues to provide a 100% valuation allowance on its deferred tax asset.

Because of the inherent uncertainties in estimating the valuation allowance on the deferred tax asset, it is at least reasonably possible that the company's estimate deferred tax asset will change in the near term and be material to the financial statements.

2006 2005

24

Current income tax benefit (expense)	\$ 7,000	\$ (7,000)
Tax benefit (expense) of temporary differences	13,000	(14,000)
Tax benefit of operating loss carryforwards	-	7,000
Decrease (increase) in valuation allowance	(20,000)	(211,000)
Total net tax benefit (expense)	\$	\$ 225,000 =======

#### (10) ACQUISITIONS OF SPORTS MEMORABILIA COLLECTION

In April 2004, the Company finalized the acquisition of a sports memorabilia collection (Collection), from it President and major shareholder. The Company recorded the Collection at \$106,000, which is the acquisition cost basis of the President and controlling shareholder.

Concurrent with the acquisition of the Collection, the Company entered into a one-year contract with a consultant to liquidate the Collection which expired in March 2005. The Company continues to explore its options to continue its liquidation of the collection.

In 2005, Management determined the sports memorabilia collection to be impaired due to lack of marketability and recorded an impairment charge of \$42,000.

The consultant has the option to purchase the Collection at any time during the term of the agreement for \$200,000 less any sale proceeds already paid to the Company. The Company computed the fair value of this call option using the Black-Scholes stock option pricing model. The following assumptions were made in estimating fair value: risk-free interest rate of 3.5%; no dividend yield; expected life of one year. The fair value calculated resulting from the issuance of this option was determined to be \$203,470 at December 31, 2004, which is recorded as a liability in the accompanying balance sheet and charged operations in the accompanying statement of operations. The Company recalculates the fair value of the option at the end of each reporting period and recognize any change as through operations and adjust its liability accordingly.

The consultant had the option to purchase the Collection at any time during the term of the agreement for \$200,000 less any sale proceeds already paid to the Company. The Company computed the fair value of this call option using the Black-Scholes stock option pricing model. The far value calculated resulting from the issuance of this option was recorded as a liability and the expense was charged to operations. The option expired in March 2005, and the Company recorded the expiration of the option liability as a gain in the accompanying statement of operations for the year end December 31, 2005.

#### (11) CORPORATE CHANGES

The Company amended its Articles of Incorporation authorizing a class of "blank check" preferred stock consisting of 5,000,000 shares thus creating a series of Series A Preferred Stock and set forth its designations, rights and preferences. The more significant right is the Series A share votes together with the holders of the common stock on all matters submitted to a vote of Company holders of common stock, with the share of Series A Preferred Stock being entitled to one

vote more than one-half of all votes entitled to be cast by all holders of voting capital stock of the Company on any matter submitted to common shareholders so as to ensure that the votes entitled to be cast by the holder of the Series A Preferred Stock are equal to at least a majority of the total of all votes entitled to be cast by the common shareholders. Each share of Series A Preferred Stock has a liquidation preference of \$.0001. In 2004, the Company issued one share of the Series A Preferred Stock to its majority common shareholder in exchange for 1,029,412 shares of common stock held by the majority common shareholder, which were surrendered to the Company and cancelled. Effective August 11, 2005, the outstanding share of the Company's Series A Preferred Stock was acquired by Eline Entertainment Group, Inc. In September 2006, the Company's majority common shareholder demanded the transfer to him of the one share of Series A preferred stock in exchange for 100,000 shares of Eline Entertainment Group, Inc. alleging breach of contract. The share certificate of Series A Preferred Stock is in the possession of the Registrant.

#### (12) SIGNIFICANT FOURTH QUARTER ADJUSTMENTS

Management determined the sports memorabilia collection to be impaired due to lack of marketability and recorded an impairment charge of \$50,402 in the fourth quarter of 2006.

F-12

# Item 8. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure.

On July 19, 2005, the Company engaged Baumann, Raymondo & Company, P.A. as its independent auditors for the year ending December 31, 2005, to replace the firm of James Moore & Co., P.L. which was dismissed as its auditors effective July 19, 2005. The decision to change auditors was approved by the Company's Board of Directors.

The reports of James Moore & Co. on the financial statements of the Company for the years ended December 31, 2003, and December 31, 2004 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

There were no disagreements with James Moore & Co., P.L., which disagreements, if not resolved to the satisfaction of James Moore & Co., P.L., would have caused it to make reference to the subject matter of the disagreement in the report, on any matters of accounting principles or practices, financial statement disclosure or auditing scope and procedures in connection with the audits of the Company's consolidated financial statements for the two-year period ended December 31, 2004, or with regard to the Company's most recent 10-QSB filed May 13, 2005.

Item 8A. Controls and Procedures.

(a) Evaluation of disclosure controls and procedures.

The Company's management, recognizes its responsibility for establishing and maintaining internal control over financial reporting for the Company. After evaluating the effectiveness of our "disclosure controls and procedures" (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of December 31, 2005 (the "Evaluation Date"), the Company's management has concluded, as of the Evaluation Date, the Company's disclosure controls and procedures were adequate and designed to ensure the information required to be

disclosed in the reports filed or submitted by us under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported with in the requisite time periods. Although the Company's existing disclosure controls and procedures are adequate, the Company's management acknowledges a material weakness may exist in those controls and procedures in that i) the accountant employed by the Company has no training regarding financial reporting and presentation rules and regulations of the SEC; and ii) the Company's President/CEO, who oversees all the accountants' work and provides all internal control functions, while possessing a MBA from the University of Florida, has no training in matters of accounting, financial reporting, or presentation rules and regulations of the SEC.

#### (b) Effectiveness of Internal Control

The Company's management is reviewing the Company's internal controls over financial reporting to determine the most suitable recognized control framework. The Company will give great weight and deference to the product of the discussions of the SEC's Advisory Committee on Smaller Public Companies (the "Advisory Committee") and the Committee of Sponsoring Organizations' task force entitled Implementing the COSO Control Framework in Smaller Businesses (the "Task Force"). Both the Advisory Committee and the Task Force are expected to provide practical, needed guidance regarding the applicability of Section 404 of the Sarbanes-Oxley Act to small business issuers. The Company's management intends to perform the evaluation required by Section 404 of the Sarbanes-Oxley Act at such time as a framework is adopted by the Company. For the same reason, the Company's registered accounting firm has not issued an "attestation report" on the Company management's assessment of internal controls. Although the Company's existing disclosure controls and procedures are adequate, the Company's management acknowledges a material weakness may exist in those controls and procedures in that i) the accountant employed by the Company has no training regarding financial reporting and presentation rules and regulations of the SEC; and ii) the Company's President/CEO, who oversees all the accountants' work and provides all internal control functions, while possessing a MBA from the University of Florida, has no training in matters of accounting, financial reporting, or presentation rules and regulations of the SEC.

(c) Changes in internal controls.

After evaluation by the Company's management, the Company's management has determined there were no significant changes in the Company's internal controls or in other factors that could significantly affect the Company's internal controls subsequent to the Evaluation Date.

Item 8B. Other Information.

None.

PART III.

Item 9. Directors, Executive Officers, Promoters, Control Persons and Corporate Governance; Compliance With Section 16(a) of the Exchange Act.

Two (2) directors, constituting the entire Board of Directors, serve until the next Annual Meeting of shareholders, or until a successor shall be elected and shall qualify:

Name	Age	Principal Occupation	Year First Became
			Director
C.E. Rick Strattan	59	President, CEO and Chairman	1990

2001

George L. Fails 60 Operations Manager

C.E. Rick Strattan, President, CEO and Director since its 1990. Mr. Strattan served as treasurer of the Company from August, 1990, to May, 1995. From November 1987 through July 1992, Mr. Strattan was with Pharmatec, Inc., where he served as Director of Marketing and Business Development for CDs. Mr. Strattan was responsible for CD sales and related business development efforts. From November, 1985 through May, 1987, Mr. Strattan served as Chief Technical Officer for Boots-Celltech Diagnostics, Inc. He also served as Product Sales Manager for American Bio-Science Laboratories, a Division of American Hospital Supply Corporation. Mr. Strattan is a graduate of the University of Florida receiving a B.S. degree in chemistry and mathematics, and has also received an MS degree in Pharmacology, and an MBA degree in Marketing/Computer Information Sciences, from the same institution. Mr. Strattan has written and published numerous articles and a book chapter on the subject of Cyclodextrins.

George L. Fails, Operations Manager CTD, Inc. since 2000. Mr. Fails currently serves as Operations Manager for CTD, Inc. Prior to joining the Company, Mr. Fails served as a Detective Sergeant with the Veterans Administration Hospital in Gainesville, Florida, with special duties as a Predator Officer with the US Marshall's Service. From 1965 until his retirement in 1986, Mr. Fails served with the US Army Special Forces, including several tours in Vietnam, Salvador, and Angola. Mr. Fails also served two years with a United States intelligence arm. Mr. Fails received his BA from the University of the Philippines, and has also received degrees from 43 Military schools, as well as the Federal police Academy in Little Rock, Arkansas.

Directors, including directors also serving the Company in another capacity and receiving separate compensation therefor shall be entitled to receive from the Company as compensation for their services as directors such reasonable compensation as the board may from time to time determine, and shall also be entitled to reimbursements for any reasonable expenses incurred in attending meetings of directors. To date, the Board of Directors has received no compensation, and no attendance fees have been paid.

Audit Committee Financial Expert

No one on our Board of Directors can be deemed to be an audit committee financial expert. Our business model is not complex and our accounting issues are straightforward. Responsibility for our operations is centralized within our executive management, which is comprised of two persons. We recognize that having a person who possesses all of the attributes of an audit committee financial expert would be a valuable addition to our Board of Directors, however, we are not, at this time, able to compensate such a person therefore, we may find it difficult to attract such a candidate.

#### Code of Ethics

We have adopted a code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Our code of ethics will be provided to any person without charge, upon request. Requests should be addressed to Investor Relations Department, c/o CTD Holdings, Inc., 27317 N.W. 78th Avenue, High Springs, Florida 32643.

Item 10. Executive Compensation.

#### SUMMARY COMPENSATION TABLE

						Long-te
		<u>A</u>	nnual compens		wards	
Name & principal	Year	Salary (\$)				4
C.E. Rick Strattan	2006	\$ 36,000	-0-	-0-	\$ 60,000.00 (6)	-0-
President, CEO	2005	\$ 36,000	\$ 30,000 (5)	-0-	\$ 76,290.00 (1)	-0-
Chairman	2004	\$ 36,000	-0-	-0-	\$ 90,833.33 (2)	-0-
George L. Fails	2006	\$ 22,800	-0-	-0-	\$ 12,000.00 (7)	-0-
Operations Manager		•	-0-			-0-
	2004	\$ 22,800	-0-	-0-	\$ 18,166.67 (4)	-0-
<ol> <li>Reflects grant of</li> </ol>	809,611 240,525 161,922 500,000	shares shares shares shares				

(7) Reflects grant of 298,644 shares

On October 14, 2003, the Company entered into a one-year Employment Agreement with C.E. Rick Strattan, the Company's president, with an annual salary of \$36,000 and \$5,000 per month in restricted common shares of the Company based on the closing value of the Company's shares on the last day of the month in which the shares are awarded. The Company has agreed to register Mr. Strattan's shares awarded pursuant to his employment contract. This contract was extended through December 31, 2007.

Effective January 1, 2004, the Company entered into a one-year Employment Agreement with George L. Fails to serve as Operations Manager. Mr. Fails is compensated \$1,900 monthly, plus \$1,000 per month in restricted common shares of the Company, based on the closing value of the Company's shares on the last day of the month in which the shares are awarded. This contract was extended through December 31, 2007.

Item 11. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table shows the ownership of the Common Stock of the Company on March 22, 2007, by each person who, to the knowledge of the Company, owned beneficially more than five percent (5%) of such stock, the ownership of each director, and the ownership of all directors and officers as a group. Unless otherwise noted, shares are subject to the sole voting and investment power of the indicated person.

Names and Address of Individual or Identity of Group	Amount and Nature of Beneficial Ownership	Approximate % of Class
C.E. Rick Strattan 4123 N.W. 46th Avenue Gainesville, FL 32606	. 4,441,466	33.88%
George L. Fails 2420 N.W. 142nd Avenue Gainesville, FL 32609	. 741,091	5.65%
Aspatuck Holdings, Inc	. 2,750,000	20.98%
All Officers and Directors as a group	. 3,890,684	66.84%
Kiaran Nicole Brooks 4123 N.W. 46th Avenue Gainesville, FL 32606	. 830,000	6.33%

Equity Compensation Plan Information

Plan category	Number of securities to be issued upon exer- cise of outstand- ing options, warrants, and and rights (a)	Weighted-average exercise price of outstanding options, warrants and rights (b)	Number of securities remaini available for futu issuance under equ compensation plans (excluding securit reflected in colum (c)
Equity compensation plans approved by security holders	None	Not Applicable	Not Applicable
Equity compensation plans not approved by security holders	* * * * * * * * * *	See Note 1 to Table (below)	* * * * * * * * *
Total			

Notes to Equity Compensation Plan Table:

Note 1 -- The Company has employment agreements terminating on December 31, 2007 with two employees. These agreements require the Company to compensate these employees, collectively, with \$6,000 per month in restricted common shares of the Company based on the closing value of the Company's shares on the last day of the month in which the shares are awarded

Item 12. Certain Relationships and Related Transactions, and Director Independence.

Mr. Strattan periodically advances the Company short-term loans and defers receipt of salary. The Company owes the stockholder \$3,467 at December 31, 2005. The loan is unsecured and interest accrues at 5%. Interest expense related to the loan totaled \$1,301 and \$3,031 for the years ended December 31, 2005 and

2004, respectively.

Item 1	.3. Exhib	pits.	
Ex	hibits		Page
(2		purchase, sale, reorganization, arrangement, ation, or succession	
(3	3) Article	es of incorporation and by-laws	
	(i) Ar	ticles of Incorporation filed August 9, 1990 *	None
	(ii) By	-Laws. *	None
	]	ertificates of Amendment to the Articles of Incorporation filed November 18, 1993 and Geptember 24, 1993. *	None
(4		ments defining the rights of security cs, including indentures	
	(a) Spe	ecimen Share Certificate for Common Stock. *	None
(9	) Voting	g Trust Agreement and amendments	None
(1	.0) Mater	cial Contracts	
	(10.1)	Agreement of Shareholders dated November 11, 1993 by and among C.E. Rick Strattan, Garrison Enterprises, Inc. and the Company. *	None
	(10.2)	Lease Agreement dated July 7, 1994**.	None
	(10.3)	Consulting Agreement dated July 29, 1994 between the Company and Yellen Associates. *	None
	(10.4)	License Agreement dated December 20, 1994 between the Company and Herbe Wirkstoffe GmbH. *	None
	(10.5)	Joint Venture Agreement between the Company and Ocumed, Inc. dated May 1, 1995, incorporated by reference to the Company's Form 10-QSB for the quarter ended June 30, 1995.**	None
	(10.6)	Extension of Agreement between the Company and Herbe Wirkstoffe GmbH.***	None
	(10.7)	Lease Extension+	
	(10.8)	Loan Agreement with John Lindsay+	
	(10.9)	Small Potatoes Contract+	
	(10.10)	Employment Agreement with C.E. Rick Strattan dated May 30, 2001++	
	(10.11)	Employment Agreement of C.E. Rick Strattan dated October 14, 2003+++	

(	10.12) Employment Agreement of George L. Fails dated October 14, 2003****	
(11)	Statement re: computation of per share earnings	Note 1(k) to Financial Statements
(13)	Annual report to security holders for the last fiscal year, Form 10-Q or 10-QSB or quarterly report to security holders	
(14)	Code of Ethics	
(16)	Letter on changes in certifying accountant***	None
(18)	Letter on change in accounting principles	None
(21)	Subsidiaries of the small business issuer	None
(22)	Published Report regarding matters submitted to vote of security holders	None
(23)	Consent of experts and counsel	None
(24)	Power of Attorney	None
(31)	Rule 13a-14(a)/15d-14a(a) Certifications****	
(32)	Section 1350 Certifications****	
(99)	Additional Exhibits	

(100) XBRL-Related Documents

\* Incorporated by reference to the Company's Form 10-SB filed with the Securities and Exchange Commission on February 1, 1994.

\*\* Incorporated by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on March 29, 1997.

\*\*\* Incorporated by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on March 28, 2000.

\*\*\*\* Filed herewith.

+ Incorporated by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on April 2, 2001.

++ Incorporated by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on April 1, 2002.

+++ Incorporated by reference to Form S-8 filed December 1, 2003.

Item 14. Principal Accountant Fees and Services.

Audit Fees

The aggregate fees billed for the last fiscal year for professional services rendered by the principal accountant, Baumann, Raymondo & Company for the audit of the Company's annual financial statements and review of financial statements

included in the Company's Form 10-QSB or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years was \$6,000.

The aggregate fees billed for each of the last two fiscal years for professional services rendered by the principal accountant, James Moore & Co., P.L. for the audit of the Company's annual financial statements and review of financial statements included in the Company's Form 10-QSB or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years was \$37,155.

Audit-Related Fees

No fees were billed during the last fiscal year for any assurance and related services by Baumann, Raymondo & Company that are not reported under the caption "Audit Fees". The nature of the services comprising the fees disclosed under this category was for accounting assistance with merger and acquisition activities.

The aggregate fees billed in each of the last two fiscal years for assurance and related services by James Moore & Co., P.L. that are reasonably related to the performance of the audit or review of the Company's financial statements and are not reported under the caption "Audit Fees" was \$1,695. The nature of the services comprising the fees disclosed under this category was for accounting assistance with merger and acquisition activities.

Tax Fees

No fees were billed during the last fiscal year for professional services rendered by Baumann, Raymondo & Company for tax compliance, tax advice, or tax planning.

The aggregate fees billed in each of the last two fiscal years for professional services rendered by James Moore & Co., P.L. for tax compliance, tax advice, and tax planning was \$3,610.

All Other Fees

No other fees were billed during the last fiscal year for professional services provided by Baumann, Raymondo & Company.

The aggregate fees billed in each of the last two fiscal years for products and services provided by James Moore & Co., P.L., other than the services reported above were \$356 in paragraphs (e)(1) through (e)(3) of this section. The nature of the services comprising the fees disclosed under this category was software training and assistance with payroll tax reporting.

#### SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CTD HOLDINGS, INC.

By: /s/ C.E. Rick Strattan

C.E. RICK STRATTAN, Chief Executive Officer Chief Operating Officer Principal Accounting Officer Date: April 2, 2007

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ C.E. Rick Strattan C.E. RICK STRATTAN Chief Executive Officer Chief Operating Officer Director Date: April 2, 2007 By: /s/ George L. Fails GEORGE L. FAILS Director Date: April 2, 2007